Wu Xi, Xing Puyuan, Shi Min, Guo Weihua, Zhao Fangping, Zhu Honglin, Xiao Jianping, Wan Jinghai, Li Junling
General Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Front Oncol. 2022 Apr 28;12:664420. doi: 10.3389/fonc.2022.664420. eCollection 2022.
Leptomeningeal metastasis (LM) commonly occurs in non-small cell lung cancer (NSCLC) patients and has a poor prognosis. Due to limited access to leptomeningeal lesions, the genetic characteristics of LM have not been explored to date. Cerebrospinal fluid (CSF) may be the most representative liquid biopsy medium to obtain genomic information from LM in NSCLC.
CSF biopsies and matched peripheral blood biopsies were collected from 33 NSCLC patients with LM. We profiled genetic alterations from LM by comparing CSF cell-free DNA (cfDNA) with plasma cfDNA. Somatic mutations were examined using targeted sequencing. Genomic instability was analyzed by low-coverage whole-genome sequencing (WGS).
Driver mutations were detected in 100% of CSF cfDNA with much higher variant allele frequency than that in matched plasma cfDNA (57.5%). Furthermore, we found that the proportions of CSF cfDNA fragments below 150 bp were significantly higher than those in plasma cfDNA. These findings indicate enrichment of circulating tumor DNA (ctDNA) in CSF and explain the high sensitivity of mutation detection in the CSF. The absence of some mutations in CSF cfDNA-especially the first-/second-generation mutation T790M, which confers resistance to epidermal growth factor receptor (EGFR)-Tyrosine kinase inhibitors (TKIs)-that were present in plasma cfDNA samples indicates different mechanisms of cancer evolution between LM and extracranial lesions. In addition, 86.6% of CSF ctDNA samples revealed high levels of genomic instability compared with 2.5% in plasma cfDNA samples. A higher number of large-scale state transitions (LSTs) in CSF cfDNA were associated with a shorter overall survival (OS).
Our results suggest that LM and extracranial lesions develop independently. Both CSF cfDNA genetic profiling and plasma cfDNA genetic profiling are necessary for clinical decision-making for NSCLC patients with LM. Through CSF-based low-coverage WGS, a high level of LSTs was identified as a potential biomarker of poor prognosis.
软脑膜转移(LM)常见于非小细胞肺癌(NSCLC)患者,预后较差。由于获取软脑膜病变组织有限,迄今为止尚未对LM的基因特征进行探索。脑脊液(CSF)可能是从NSCLC患者的LM中获取基因组信息的最具代表性的液体活检介质。
收集了33例NSCLC合并LM患者的CSF活检样本和匹配的外周血活检样本。通过比较CSF游离DNA(cfDNA)与血浆cfDNA,对LM的基因改变进行分析。使用靶向测序检测体细胞突变。通过低覆盖度全基因组测序(WGS)分析基因组不稳定性。
在100%的CSF cfDNA中检测到驱动突变,其变异等位基因频率远高于匹配的血浆cfDNA(57.5%)。此外,我们发现CSF中低于150 bp的cfDNA片段比例显著高于血浆cfDNA。这些发现表明CSF中循环肿瘤DNA(ctDNA)富集,并解释了CSF中突变检测的高灵敏度。CSF cfDNA中某些突变的缺失,尤其是血浆cfDNA样本中存在的赋予对表皮生长因子受体(EGFR)-酪氨酸激酶抑制剂(TKIs)耐药性的第一代/第二代突变T790M,表明LM与颅外病变之间存在不同的癌症进化机制。此外,86.6%的CSF ctDNA样本显示出高水平的基因组不稳定性,而血浆cfDNA样本中这一比例为2.5%。CSF cfDNA中较高数量的大规模状态转换(LSTs)与较短的总生存期(OS)相关。
我们的结果表明,LM与颅外病变独立发展。对于NSCLC合并LM的患者,CSF cfDNA基因分析和血浆cfDNA基因分析对于临床决策均有必要。通过基于CSF的低覆盖度WGS,高水平的LSTs被确定为预后不良的潜在生物标志物。